Summit on Future Treatments in Migraine and Cluster Headaches
Findings from an AMCP Market Insights Program
Headache is one of the most common symptoms in the general population, but despite its high prevalence and impairment, migraine is often not recognized or effectively treated. Fortunately, with aid from advanced technology and clinical innovations, there are new treatment options available for patients - including CGRP inhibitors and to other therapies headed for Food and Drug Administration (FDA) approval, and a growing class of non-pharmaceutical devices that work via nerve stimulation. As new classes of drugs and nondrug treatments come to market health care providers and payers will need up-to-date evidence and guidance for the use and coverage of novel treatments.
To understand the appropriate and cost effective use of novel treatments, AMCP convened an expert forum of stakeholders. Forum participants included representatives from regional and national health plans, integrated delivery networks, 340b entities and pharmacy benefit managers. Participants discussed the differentiation of migraine and cluster headaches, treatment and prevention therapies, pipeline pharmaceuticals and devices, and the impact of new treatments on formulary management and the delivery of care.